FOURTH AMENDMENT TO COLLABORATION AGREEMENTCollaboration Agreement • November 13th, 2018 • Surface Oncology, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledNovember 13th, 2018 Company IndustryThis Fourth Amendment (the “Fourth Amendment”) to the Agreement (as defined below), is entered into as of October 9, 2018 (the “Amendment Effective Date”), by and between Surface Oncology, Inc., a corporation organized and existing under the Laws of the State of Delaware (“Surface”), and Novartis Institutes for BioMedical Research, Inc., a corporation organized and existing under the Laws of the State of Delaware (“Novartis”).
FIRST AMENDED AND RESTATED DEVELOPMENT AND OPTION AGREEMENTDevelopment and Option Agreement • November 13th, 2018 • Surface Oncology, Inc. • Biological products, (no disgnostic substances) • Massachusetts
Contract Type FiledNovember 13th, 2018 Company Industry JurisdictionThis First Amended and Restated Development and Option Agreement (this “Agreement”) made effective as of October 3, 2018 (the “Amended Effective Date”), is entered into by and between Adimab, LLC, a Delaware limited liability company having an address at 7 Lucent Drive, Lebanon, NH 03766 (“Adimab”), and Surface Oncology, Inc., a Delaware corporation having an address at 25 First Street, Suite 303, Cambridge, MA 02141 (“Surface”).